, /PRNewswire/ -- (Nasdaq: ) today announced the launch of a new sprinkle formulation of , the #1 prescribed vesicular monoamine transporter 2 (VMAT2) inhibitor indicated for the treatment of adults with tardive dyskinesia and chorea associated with Huntington's disease. INGREZZA SPRINKLE (valbenazine) capsules is now available through the same network of specialty and local affiliated pharmacies that distribute INGREZZA. "Only INGREZZA offers a sprinkle formulation to ease administration for individuals living with tardive dyskinesia or Huntington's disease chorea, who often have difficulty swallowing pills," said Eiry W.
Roberts, M.D., Chief Medical Officer, Neurocrine Biosciences.
"We wanted to provide this new option to patients and their caregivers who want the benefit of treatment with INGREZZA without the challenge of swallowing a capsule." INGREZZA and INGREZZA SPRINKLE offer simple dosing that's always one capsule, once daily with no complex dose adjustments to get to an effective dose. Only INGREZZA and INGREZZA SPRINKLE offer a therapeutic dose from day one.
INGREZZA SPRINKLE offers the same three simple and effective dosing options (40 mg, 60 mg and 80 mg) as INGREZZA, which can be adjusted by a healthcare provider based on patient response and tolerability. The INGREZZA SPRINKLE capsule is easy to open and the contents (granules) can be sprinkled on soft food, such as applesauce, yogurt or pudding, for oral administration. Proper preparation and administration of.
